Herpes Zoster Neuralgia
Conditions
Interventions
stimulation site: the M1 area of the motor cortex
stimulation duration: 20 minutes.
Control Group Y :Take 150 mg of pregabalin in the morning and evening every day as usual, and take 0.5 mg of mecobalamin orally in the morning, at noon and in the evening.
Control Group N:On the basis of the conventional drug Group Y, conduct nerve block treatment according to the patients pain site. After determining the segment, administer 5 ml of an analgesic compoun
Control Group S:On the basis of the treatment in Group N, conduct sham rTMS treatment on the patients, that is, use a sham magnetic stimulation coil. Its appearance and the sound it makes during opera
Observation Group R:The basic treatment is the same as that in Group Y. On this basis, it is combined with pulsed radiofrequency treatment of the dorsal root ganglion and simultaneously with rTMS trea
stimulation intensity: 80%-100% of the motor threshold (MT)
total number of pulses: 2000 pulses
Observation Group T:The basic treatment is the same as that in Group N. On this basis, it is combined with rTMS treatment. That is, the patients participating in the treatment receive magnetic stimula
Sponsors
The First Affiliated Hospital of Ningbo University
Eligibility
Sex/Gender
All
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: Patients with herpes zoster neuralgia who are over 50 years old; those who meet the diagnostic criteria for herpes zoster neuralgia and have a disease course within 3 months; whose pain intensity has a Visual Analogue Scale (VAS) score of more than 5 points; who are able to correctly assess their pain condition; and who voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: Patients with epilepsy and those with a family history of epilepsy; those with a history of craniocerebral surgery; those with metal implants in the brain; those with implanted cardiac pacemakers; patients with severe diseases of the heart, lungs, liver and kidneys; and those with coagulation disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| PGIC;SF- MPQ;The average dose of pregabalin;PSQI;The number of nerve blocks; | — |
Countries
China
Contacts
Public ContactLin Huidan
The First Affiliated Hospital of Ningbo University
Outcome results
None listed